Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Kim M. Linton^*, Umberto Vitolo, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raul Cordoba, David John Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan Manuel Sancho, Tara Cochrane, Sirpa Leppä, Martine E.D. Chamuleau, Diana Gernhardt, Işıl AltıntaşYan Liu, Tahamtan Ahmadi, Minh H. Dinh, Daniela Hoehn, Elena Favaro, Brian Elliott, Catherine Thieblemont, Julie M. Vose

^*Corresponding author for this work

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

2 Meeting Abstract

2 results

Filter

2024
P1121 MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VSMOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES
Linton, K. & et al., 14 Jun 2024, In: HemaSphere. 18, S1, p. 2039-2040
Research output: Contribution to journal › Meeting Abstract › peer-review

Open Access
2023
1655 Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Linton, K., 9 Dec 2023, In: Blood.
Research output: Contribution to journal › Meeting Abstract › peer-review

Open Access

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Research output

Search results

P1121 MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VSMOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

1655 Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort